Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03039231 · ClinicalTrials.gov registry record · NA

Investigation of the Freespira Breathing System in the Treatment of Post Traumatic Stress Disorder (PTSD)

A NA study of Stress Disorders, Post-Traumatic, sponsored by Palo Alto Health Sciences.

Completed
Registry status
NA
Development phase
55
Enrollment target
1
Study location

NCT03039231: Completed NA study of Stress Disorders, Post-Traumatic, sponsored by Palo Alto Health Sciences.

NCT03039231 is a NA study of Stress Disorders, Post-Traumatic that has completed, run by Palo Alto Health Sciences. The registered enrollment target is 55 participants, below the 155-participant average among 66 other Stress Disorders, Post-Traumatic trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03039231, a NA study of Stress Disorders, Post-Traumatic, has completed, sponsored by Palo Alto Health Sciences.

COMPLETED
Registry status
NA
Development phase
55 participants
Enrollment target
1
Study location

Study Summary

This study will test the efficacy of the Freespira Breathing System in adults with post traumatic stress disorder (PTSD).

Primary Outcome

Using this scale, Response is defined as a reduction of 6 or more points. Remission is defined as Response plus no longer meeting clinical symptom criteria and having a severity score \< 25.

Interventions

  • DEVICE Freespira Breathing System

Study Locations (1)

California

  • Stanford University School of Medicine/Palo Alto Veterans Institute for Research - Palo Alto

Trial Details

FieldValue
Enrollment Target 55 participants
Start Date 2017-02-01
Est. Completion 2019-08-25
Phase NA
Palo Alto Health Sciences

2 total trials

What the finished NCT03039231 record still lists

NCT03039231 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 155-participant average among 66 other Stress Disorders, Post-Traumatic trials with a reported enrollment target (65% lower).

The record links to 1 condition, with Stress Disorders, Post-Traumatic appearing as the primary indexed condition, and to 1 intervention - of which Freespira Breathing System is the first listed.

NCT03039231 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT03039231 about?

NCT03039231 is a clinical study titled "Investigation of the Freespira Breathing System in the Treatment of Post Traumatic Stress Disorder (PTSD)". This study will test the efficacy of the Freespira Breathing System in adults with post traumatic stress disorder (PTSD).

What is the current status of trial NCT03039231?

This trial is currently completed. It is a NA study. The enrollment target is 55 participants. The study started on 2017-02-01. Estimated completion is 2019-08-25.

What conditions does trial NCT03039231 study?

This clinical trial studies the following conditions: Stress Disorders, Post-Traumatic.

What interventions are being tested in trial NCT03039231?

The interventions under investigation include: Freespira Breathing System (DEVICE).

Who is sponsoring clinical trial NCT03039231?

This trial is sponsored by Palo Alto Health Sciences, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03039231 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stress Disorders, Post-Traumatic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03039231's enrollment target sits among peer trials

55 47th of 66 higher than 20 of 66 other Stress Disorders, Post-Traumatic trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Stress Disorders, Post-Traumatic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01638676 · 55 participants · Phase 1

    A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients

  • NCT01906385 · 55 participants · Phase 1

    Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

  • NCT03007030 · 55 participants · Phase 2

    Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery

  • NCT03152058 · 55 participants · Phase 2

    IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03039231, the US trial registry maintained by the National Library of Medicine. NCT03039231 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.